Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy

doi:10.3748/wjg.v23.i11.2060

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10354)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

585

WORD

329

HTML

5311

Figures (1-3)

312

Tables (1-3)

331

Sum=6868

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1259

Download

2227

Sum=3486

Mar 21, 2017 (publication date) through Mar 10, 2025

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Mar 21, 2017; 23(11): 2060-2067
Published online Mar 21, 2017. doi: 10.3748/wjg.v23.i11.2060

Table 1 Clinical characteristics of gastroesophageal reflux disease patients

Background factors	The number of applicable subjects for the factor
Erosive esophagitis/NERD	19/20
Gender (male/female)	17/22
Atrophic gastritis (+/-)	20/19
Hiatal hernia (+/-)	24/15
Alcohol consumption habit (+/-/unknown)	16/21/2
Smoking habit (+/-/unknown)	4/33/2
PPI types (omeprazole/lansoprazole/rabeprazole/unknown)	5/11/22/1
PPI dose (half/full/double/unknown)	8/26/4/1
Concomitant drug against GERD (+/-)	14/25
Ca antagonist (+/-)	15/24
ASA (+/-)	7/32
NSAIDs (+/-)	2/37
CYP2C19 genotype (RM/IM/PM/unknown)	13/20/5/1
Maintenance PPI therapy period (< 6 mo/6-12 mo/> 12 mo)	3/1/35
Age (mean ± SD)	68.5 ± 11.9
BMI (mean ± SD)	22.7 ± 3.1

GERD: Gastroesophageal reflux disease; NERD: Non-erosive reflux disease; PPI: Proton pump inhibitor; ASA: Acetylsalicylic acid; NSAIDs: Non-steroidal anti-inflammatory drugs; CYP2C19: Cytochrome P450 2C19; RM: Rapid metabolizer; IM: Intermediate metabolizer; PM: Poor metabolizer; BMI: Body mass index.

Citation: Kawara F, Fujita T, Morita Y, Uda A, Masuda A, Saito M, Ooi M, Ishida T, Kondo Y, Yoshida S, Okuno T, Yano Y, Yoshida M, Kutsumi H, Hayakumo T, Yamashita K, Hirano T, Hirai M, Azuma T. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy. World J Gastroenterol 2017; 23(11): 2060-2067
URL: https://www.wjgnet.com/1007-9327/full/v23/i11/2060.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i11.2060